Sangamo Therapeutics (SGMOQ) EBITDA Margin (2010 - 2025)

Sangamo Therapeutics' EBITDA Margin history runs 16 years deep, the most recent figure standing at 268.51% for Q4 2025.

• On a quarterly basis, EBITDA Margin rose 13134.0% year-over-year to 268.51% in Q4 2025; TTM through Dec 2025 was 306.53%, a 12332.0% decrease from a year earlier, with the FY2025 full-year figure at 306.53%, down 12665.0% from the prior year.
• EBITDA Margin rose to 268.51% in Q4 2025 per SGMOQ's latest filing, from 6119.28% in the prior quarter.
• Across five years, EBITDA Margin topped out at 21.52% in Q3 2024 and bottomed at 10712.27% in Q1 2024.
• The 5-year median for EBITDA Margin is 205.44% (2022), against an average of 1790.54%.
• Across the five-year window, EBITDA Margin plunged 1072368 bps in 2024 and jumped 1031932 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 142.57% in 2021, then slumped by 43 bps to 203.42% in 2022, then slumped by 1394 bps to 3039.13% in 2023, then surged by 87 bps to 399.85% in 2024, then surged by 33 bps to 268.51% in 2025.
• Per Business Quant, the three latest SGMOQ EBITDA Margin figures stand at 268.51% (Q4 2025), 6119.28% (Q3 2025), and 97.54% (Q2 2025).